potassium-magnesium-aspartate and Arrhythmias--Cardiac

To investigate the protective effects of potassium magnesium aspartate against oxidative stress status and lipid oxidative damage in the patients with angina and arrhythmia due to coronary artery disease, its therapeutic effect on arrhythmia and its possible mechanism.. With single blind protocol, 98 patients with angina and arrhythmia due to coronary artery disease were randomly divided into (1)Experiment group (n = 65), who received routine remedy for coronary heart disease plus potassium magnesium aspartate. (2)Control group (n = 33), who received only routine therapy for coronary heart disease without potassium magnesium aspartate. Reduced glutathione (GSH), oxidized glutathione (GSSG), malondialdehyde (MDA) and oxidized low density lipoprotein (ox-LDL) in plasma of all patients were examined before and one week after treatment, all patients with arrhythmia were equipped with Holter for continuous monitoring of cardiac rhythm.. After one week's treatment, the GSH level in plasma of experiment group and the ratio of GSH and GSSG (GSH/GSSG) were significantly increased comparing with control group (both P<0.01), while GSSG, MDA and ox-LDL levels significantly lowered comparing with control group(all P<0.01). The premature beats diminished 86.5% in experiment group, but the decrease rate in control group was only 47.4% (P<0.01). The improvement in indexes of oxidative stress status (including GSH/GSSG, MDA and ox-LDL) and the reduction of premature beats showed close correlation with each other (all P<0.01). No adverse effects of the drug were found after one week of administration of Potassium magnesium aspartate.. Potassium magnesium aspartate can strikingly improve oxidative stress status and decrease lipid oxidative damage in the patients with coronary heart disease, and the frequent premature beats were also significantly reduced by potassium magnesium aspartate. The analysis of above results reveals an intrinsic relationship between the improvement of oxidative stress status and the good therapeutic effects on frequent premature beats by potassium magnesium aspartate, which may suggest an involvement of oxidative stress in the pathogenesis of arrhythmias.

Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Arrhythmias, Cardiac; Cardiotonic Agents; Female; Glutathione; Glutathione Disulfide; Humans; Lipid Peroxidation; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Potassium Magnesium Aspartate; Single-Blind Method

In a prospective randomized clinical trial we tested the efficiency of different electrolyte infusions for the treatment of intraoperatively occurring isorhythmic AV dissociation (ID). Only infusions containing Mg were effective in restoring sinus rhythm: the infusion of K-Mg aspartate led to a conversion of intraoperatively occurring ID into sinus rhythm in 72% (p less than 0.01) of the patients and the infusion with Mg aspartate alone did so in 67% (p less than 0.01) of the patients. The rate of spontaneous conversion was 22% in the control group treated with Ringer's solution. The use of infusions containing K aspartate was ineffective in restoring sinus rhythm.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Arrhythmias, Cardiac; Aspartic Acid; Biometry; Electrolytes; Female; Hemodynamics; Humans; Intraoperative Complications; Male; Middle Aged; Potassium Magnesium Aspartate

The aim of this study was to determine if the potassium aspartate and magnesium (PAM) prevent reperfusion-induced ventricular arrhythmias (RIVA) in ischemia-reperfusion (IR) rabbit heart. Thirty rabbits were randomly divided into control, ischemia and PAM groups. Arterially-perfused rabbit left ventricular preparations were made, and transmural ECG as well as action potentials from both endocardium and epicardium were simultaneously recorded in the whole process of all experiments. In control group rabbit ventricular wedge preparations were continuously perfused with Tyrode's solution, and in ischemia group and PAM groups the perfusion of Tyrode's solution was stopped for 30 min. Then the ischemia group was reperfused with Tyrode's solution and the PAM group with Tyrode's solution containing 2.42 mg/L PAM, respectively. ECG, QT interval, transmural repolarization dispersion (TDR) and action potentials from epicardium and endocardium were simultaneously recorded, and the RIVA of the wedge preparation was observed. Compared with control group, TDR and incidence of RIVA were significantly increased in ischemia group (P<0.05). The incidence of RIVA in control, ischemia and PAM group was 0/10, 9/10 and 1/10, respectively. Compared with ischemia group, TDR and incidence of RIVA were significantly reduced in PAM group (P<0.05). Potassium aspartate and magnesium significantly reduce TDR and prevent ventricular arrhythmia in ischemic rabbit heart.

Topics: Animals; Arrhythmias, Cardiac; Female; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Potassium Magnesium Aspartate; Rabbits; Random Allocation

Kalium and Magnesium ions are important cations in human body, both of them take part in many processes of metabolism in coordination. Injection of Kalii L-aspartatis and Magnesii L-aspartatis added to polarized liquid (GIK-Glucose, Insulin, Kalii Chlorid) might potentiate its effect and reduce carbon dioxide and ammonia in blood. 72 patients with various heart emergencies and other critical diseases were treated with potentiated polarized liquid (GIKL) with remarkable efficacy. A preliminary study on its clinical use and mechanism was carried out.

Topics: Adult; Aged; Arrhythmias, Cardiac; Cardioplegic Solutions; Female; Glucose; Heart Failure; Humans; Insulin; Male; Middle Aged; Potassium; Potassium Magnesium Aspartate; Respiratory Insufficiency

Topics: Acute Disease; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Female; Humans; Lidocaine; Male; Middle Aged; Myocardial Infarction; Potassium Magnesium Aspartate

The article analyses 188 cases treated for acute left ventricular insufficiency (ALVI) in different forms of tachyarrhythmia. It was established that in patients with supraventricular paroxysmal tachycardia ALVI develops when the rate of cardiac contractions is 180 +/- 3/min on the average, whereas in patients with cardiac fibrillation it develops when the rate of contractions is 163 +/- 4/min. For successful treatment of ALVI of a tachyarrhythmic character it is necessary to restore the sinus rhythm or slow down the rhythm of cardiac contractions in patients with supraventricular paroxysmal tachycardia to 113 +/- 5/min on the average and in patients with cardiac fibrillation to 118 +/- 2/min. Isoptin and obsidan produce the highest decelerating effect. In half of the patients with tachyarrhythmia. ALVI was relieved by means of antiarrhythmic agents among which obsidan and isoptin proved most effective.

Topics: Acute Disease; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Drug Therapy, Combination; Electric Countershock; Female; First Aid; Heart Failure; Humans; Male; Middle Aged; Potassium Magnesium Aspartate; Procainamide; Propranolol; Strophanthins; Verapamil

Topics: Aged; Arrhythmias, Cardiac; Aspartic Acid; Female; Humans; Male; Middle Aged; Myocardial Infarction; Potassium Magnesium Aspartate

Topics: Arrhythmias, Cardiac; Asparagine; Heart; Humans; Magnesium; Potassium; Potassium Magnesium Aspartate